24 25 We did subgroup analysis and assessments of publication bias for outcomes with 10 or more trials or comparison groups.
The most current version of the review (Update 4) contains only one more trial by Unrod (2007) for this comparison.
There were 20 trial comparisons (Table 2).
Clearly, there is a compelling need for more trials, with head-to-head comparisons, to provide convincing evidence of the benefit and safety of a specific, potentially life-long prophylactic regimen.
In indirect comparisons with substantially more trials, tetracycline appeared to have larger benefits than doxycycline, norfloxacin and trimethoprim-sulfamethoxazole for the primary review outcomes.
This makes cross-trial comparisons more difficult, since eligibility criteria for trials in mCRPC have historically focused on either chemonaive or chemo-pretreated populations.
A slightly higher repeatability in Cycle1-2009 was observed for location G-L4 (Table 6), which involved more trials, i.e. more genotypes, in comparison with other locations in Germany.
There were more trials in the latter category (12) than in the comparison with control conditions (7), but these were still a minority.
Significantly more trials that mentioned an SAE occurring documented that a DSMB was present in comparison to trials with no SAEs (55/210 vs 14/372 trials, p < 0.05).
